Page last updated: 2024-09-05

sorafenib and Melanoma

sorafenib has been researched along with Melanoma in 123 studies

Research

Studies (123)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	40 (32.52)	29.6817
2010's	77 (62.60)	24.3611
2020's	6 (4.88)	2.80

Authors

Authors	Studies
Dalton, JT; Li, W; Lu, Y; Miller, DD; Wang, Z	1
Chen, J; Dalton, JT; Li, W; Lu, Y; Miller, DD; Wang, Z	1
Cho, SJ; Choi, JH; Hah, JM; Kim, DJ; Kim, H; Lee, SH; Nam, BS; Oh, CH; Sim, TB; Yoo, KH	1
Davies, L; Dijkstra, HP; Friedlos, F; Gill, A; Kirk, R; Manne, HA; Marais, R; Ménard, D; Niculescu-Duvaz, D; Niculescu-Duvaz, I; Nourry, A; Roman, E; Springer, CJ; Suijkerbuijk, BM; Taylor, RD; Whittaker, S; Zambon, A	1
Baek, D; Cho, JH; Choi, WK; El-Gamal, MI; Hah, JM; Jung, MH; Kim, H; Lee, SH; Oh, CH; Park, JH; Sim, TB; Yoo, KH	1
Cho, JH; Choi, JH; El-Gamal, MI; Hah, JM; Hong, JH; Jung, MH; Kim, H; Kim, HJ; Lee, SH; Oh, CH; Sim, TB; Yoo, KH	1
Chung, JY; Hah, JM; Kim, H; Lee, J; Oh, CH; Sim, T; Yoo, KH; Yu, H	1
Hah, JM; Jung, Y; Kim, H; Lee, J; Oh, CH; Sim, T; Yoo, KH; Yu, H	1
Cho, SJ; Hah, JM; Kim, DJ; Kim, H; Lee, J; Lee, SH; Nam, BS; Oh, CH; Sim, TB; Tae, J; Yoo, KH	1
Hah, JM; Kim, H; Kim, M; Kim, MH; Sim, T; Yoo, KH; Yu, H	1
El-Gamal, MI; Jung, MH; Lee, WS; Oh, CH; Sim, T; Yoo, KH	1
Baek, D; Choi, HS; Choi, WK; El-Gamal, MI; Oh, CH	1
Hah, JM; Kim, H; Kim, M; Lee, J; Yu, H	1
El-Gamal, MI; Lee, YS; Oh, CH; Park, JH	1
Li, CY; Li, QS; Lu, X; Zhang, H; Zhu, HL	1
Cho, HJ; El-Gamal, MI; Hah, JM; Kim, H; Kim, HJ; Lee, SH; Oh, CH; Sim, T; Yoo, KH	1
Abdel-Maksoud, MS; El-Gamal, MI; Jung, MH; Oh, CH; Sim, T; Yoo, KH	1
Dong, JJ; Li, QS; Lv, XH; Yang, Y; Zhang, YB; Zhou, WP; Zhu, HL	1
Choi, HS; El-Gamal, MI; Hong, JH; Kim, G; Koh, EJ; Lee, SG; Lee, SH; Oh, CH; Sim, T; Yoo, KH	1
Chen, K; Li, B; Shen, J; Wang, G; Wang, H; Xu, Z; Yang, M; Zeng, B; Zhu, W	1
Chen, Y; Lu, T; Mao, T; Tang, W; Wang, L; Zhang, L; Zhang, Q; Zhang, Z; Zhi, Y; Zhou, X; Zhu, G	1
Li, Z; Liu, P; Niu, F; Qian, L; Ren, Y; Wang, C; Wang, J; Xiong, Y; Yan, Y; Ye, Q; Yu, Y	1
Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM	1
Antunes, F; Bincoletto, C; Buri, MV; Chammas, R; Corazzari, M; Fimia, GM; Gagliardi, M; Pereira, GJS; Piacentini, M; Saito, RF; Smaili, SS	1
Jung, KE; Kim, CD; Kim, KI; Shin, YB; Yoon, TJ	1
Anbar, HS; El-Gamal, MI; Jeon, HR; Kwon, D; Lee, BS; Oh, CH; Tarazi, H	1
Ebrahim, S; Hashemi, S; Moosavi, MA; Motamedi, M; Rahmati, M	1
Heinzerling, L; Janka, R; Kaempgen, E; Knieling, F; Neurath, MF; Scheulen, ME; Schuler, G; Strobel, D; Sturm, J; Wildner, D	1
Lim, SY; Menzies, AM; Rizos, H	1
Moorthy, A; Srivastava, A	1
In, GK; Ricker, C; Snow, A	1
Pavlick, AC	1
Allegra, M; Bahadoran, P; Ballotti, R; Giacchero, D; Hofman, P; Lacour, JP; Le Duff, F; Long-Mira, E; Passeron, T	1
Degen, A; Egberts, F; Garbe, C; Gutzmer, R; Hauschild, A; Kilian, K; Poppe, LM; Trefzer, U; Ugurel, S; Weichenthal, M	1
Allegra, M; Bahadoran, P; Ballotti, R; Bastian, BC; Bollag, G; Botton, T; Burton, EA; Garrido, MC; LeBoit, PE; McCalmont, TH; Nelson, T; Rocchi, S; Sparatta, A; Vemula, SS; Yeh, I	1
Aupérin, A; Ayyoub, M; Caignard, A; Caillat-Zucman, S; Chaba, K; Chaput, N; Dessen, P; Eggermont, A; Flament, C; Jacquelot, N; Jacques, Y; Mateus, C; Messaoudene, M; Mortier, E; Poirier-Colame, V; Porta, C; Robert, C; Romero, AI; Rusakiewicz, S; Valmori, D; Vielh, P; Zitvogel, L	1
Bhinder, A; Carson, WE; Clinton, SK; Geyer, S; Kendra, K; Lam, E; Lesinski, GB; Mace, TA; Monk, P; Mortazavi, A; Olencki, T; Tahiri, S	1
Holderfield, M; Nagel, TE; Stuart, DD	1
D'Andrea, K; Flaherty, KT; Kirkwood, JM; Kluger, HM; Lee, SJ; Letrero, R; Nathanson, KL; Rimm, DL; Schuchter, LM; Wilson, MA; Zhao, F	1
Aigner, B; Artl, M; Niederkorn, A; Richtig, E; Schwantzer, G; Wackernagel, W	1
Beeram, M; Benjamin, D; Ketchum, N; Mahalingam, D; Malik, L; Michalek, J; Mita, A; Rodon, J; Sankhala, K; Sarantopoulos, J; Tolcher, A; Wright, J	1
Gadot, N; Lassau, N; Leguerney, I; Pénault-Llorca, F; Robin, N; Scoazec, JY; Victorin, S	1
Anseth, KS; Jones, CE; Leight, JL; Lin, AJ; Tokuda, EY	1
Aldridge, J; Atkins, MB; Conley, C; Flaherty, KT; Giobbie-Hurder, A; Hodi, FS; Ibrahim, N; Lawrence, DP; McDermott, DF; Mier, JW; Sullivan, RJ	1
Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT	1
Afaq, F; Agarwal, J; Athar, M; Baxter, RD; Elmets, CA; Hunt, KM; Pal, HC	1
D'Andrea, K; Flaherty, KT; Khare, S; Kirkwood, JM; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Roszik, J; Schuchter, LM; Wilson, MA; Woodman, SE; Wubbenhorst, B; Zhao, F	1
Afaq, F; Athar, M; Diamond, AC; Elmets, CA; Kappes, JC; Katiyar, SK; Pal, HC; Strickland, LR	1
Henderson, M; Heriot, AG; Knowles, J; Lynch, AC; Warrier, SK	1
Fiskus, W; Mitsiades, N	1
Okano, S	1
Chen, H; Fisher, DE; Li, Y; Sun, J; Westover, KD; Xia, Y; Zhang, J	1
Delcambre, C; Dutriaux, C; Heutte, N; Joly, F; Lesimple, T; Mouriaux, F; Neidhart-Berard, EM; Parienti, JJ; Penel, N; Peyro Saint Paul, L; Pham, AD; Piperno-Neumann, S; Servois, V; Thyss, A	1
Kester, M; Robertson, GP; Smith, CD; Tran, MA	1
Egberts, F; Hauschild, A; Kahler, KC; Livingstone, E	1
Amaravadi, R; Fecher, LA; Schuchter, LM	1
Alexandrescu, DT; Dasanu, CA; Farzanmehr, H; McClure, R	1
Bar-Eli, M; Melnikova, VO	1
Jorda, E; Lopez, V; Marti, N; Monteagudo, C; Pinazo, I	1
Elder, DE; Flaherty, KT; Herlyn, M; Letrero, R; Nathanson, KL; Nguyen, TK; Smalley, KS; Van Belle, P; Villanueva, J; Wang, Y; Xiao, M	1
Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N	1
Hwu, P; Kim, K; Lazar, AJ; Quintás-Cardama, A; Ross, M; Woodman, SE	1
Poust, J	1
Camp, RL; Flaherty, KT; Jilaveanu, L; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Zito, C	1
Lee, F; Richmond, A; Smykla, R; Thu, YM; Yang, J; Zaja-Milatovic, S	1
Dhomen, N; Marais, R	1
Frieling, T; Heise, J; Wassilew, SW	1
Flaherty, KT; Smalley, KS	1
Subbiah, V; Wolff, JE	1
Aziz, SA; Camp, RL; Conrad, PJ; Jilaveanu, LB; Kluger, HM; Rimm, DL; Schmitz, JC; Sznol, M; Zito, CR	1
Gil, R; Grueso, J; Hernandez-Losa, J; López-Fauqued, M; Moliné, T; Pujol, A; Recio, JA	1
DeNicola, GM; Karreth, FA; Tuveson, DA; Winter, SP	1
Bertsch, A; Henneges, C; Jung, S; Kohlbacher, O; Nahnsen, S; Nordheim, A; Pfeifer, N; Zerck, A	1
Hurlstone, A; Wellbrock, C	1
Dobrovic, A; Hamilton, AL; Handolias, D; Kerr, L; McArthur, GA; Moodie, K; Salemi, R; Tan, A	1
Burger, AM; Egorin, MJ; Heilbrun, LK; Horiba, MN; Ivy, P; Li, J; Lorusso, PM; Pacey, S; Sausville, EA; Vaishampayan, UN	1
Ali-Osman, F; Augustine, CK; Beasley, GM; Burchette, J; Jung, SH; McMahon, N; Padussis, J; Pruitt, SK; Selim, MA; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA	1
Degen, A; Gutzmer, R; Hauschild, A; Kapp, A; Satzger, I; Voelker, B	1
Beck, D; Berger, A; Flaherty, K; Garbe, C; Gogel, J; Kulms, D; Lasithiotakis, K; Maczey, E; Mauthe, M; Meier, F; Niessner, H; Proikas-Cezanne, T; Schadendorf, D; Schaller, M; Schittek, B; Sinnberg, T; Toulany, M; Venturelli, S	1
Rosen, N; Solit, D	1
Nelson, KC; Puri, PK; Raymond, AK; Selim, MA; Tyler, DS	1
Buckley, M; Christos, PJ; Goldberg, L; Hamilton, A; Liebes, L; Min, C; Osman, I; Ott, PA; Pavlick, AC; Polsky, D; Safarzadeh-Amiri, S; Wright, JJ; Yee, H; Yoon, J	1
Becker, JC; Berking, C; Degen, A; Egberts, F; Frey, L; Garbe, C; Gutzmer, R; Hassel, JC; Hauschild, A; Kaehler, KC; Livingstone, E; Mauch, C; Mohr, P; Rass, K; Schadendorf, D; Schenck, F; Trefzer, U; Ugurel, S; Weichenthal, M; Wilhelm, T	1
Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D	1
Fliegel, L; Karki, P; Li, X; Schrama, D	1
Flaherty, KT; Frye, RF; Lathia, C; O'Dwyer, PJ; Redlinger, M; Rosen, M; Schuchter, L	1
Bell, JC; Breitbach, CJ; Falls, T; Heo, J; Hickman, T; Hwang, TH; Kim, CW; Kim, MK; Kirn, DH; Lee, YK; Moon, A; Oh, SY; Parato, K; Patt, R; Rhee, BG; Rintoul, J; Woo, HY	1
Bertolotto, C; Bourcier, C; Grépin, R; Griseri, P; Mazure, N; Pagès, G	1
Boulinguez, S	1
Affolter, A; Ahmad, T; Chao, D; Chevreau, C; Corrie, P; Eisen, T; Gibbens, I; Gore, ME; Harries, M; James, MG; Jouary, T; Lorigan, P; Marais, R; Montegriffo, E; Nathan, PD; Negrier, S; Ottensmeier, C; Prendergast, S; Robert, C; Strauss, UP	1
Bedeir, A; Berger, W; Ghassemi, S; Grasl-Kraupp, B; Grusch, M; Heffeter, P; Heinzle, C; Held, G; Holzmann, K; Marian, B; Metzner, T; Micksche, M; Peter-Vörösmarty, B; Pirker, C; Spiegl-Kreinecker, S	1
Bollag, G	1
Chan, JL; Chen, S; Goydos, JS; Lee, HJ; Namkoong, J; Rosenberg, S; Shin, SS; Wall, BA; Wangari-Talbot, J	1
Liu, Q; Mier, JW; Panka, DJ	1
Cho, HG; Choi, HS; El-Gamal, MI; Hong, JH; Oh, CH; Yoo, KH	1
Doudican, NA; Orlow, SJ; Quay, E; Zhang, S	1
Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Deville, A; Giacchero, D; Lacour, JP; Ortonne, JP; Passeron, T; Ségalen, C; Thyss, A	1
Bassett, RL; Bedikian, AY; Culotta, KS; Dancey, JE; Davies, MA; Deng, W; Fox, PS; Gupta, S; Huang, S; Hwu, P; Hwu, WJ; Kim, KB; Lazar, AJ; Liu, W; Madden, TL; Ng, CS; Papadopoulos, NE; Prieto, VG; Wright, JJ; Xu, Q	1
Akerley, WL; Flaherty, LE; Kirkwood, JM; Lao, CD; Margolin, KA; Moon, J; Othus, M; Sondak, VK; Sosman, JA	1
Dummer, R; Karpova, MB; Levesque, MP; Mangana, J	1
Augustine, C; Beasley, GM; Brady, MS; Coleman, AP; Davies, MA; Peterson, BL; Raymond, A; Sanders, G; Selim, MA; Tyler, DS	1
Avril, MF; Billemont, B; Blanchet, B; Coriat, R; Franck, N; Goldwasser, F; Lebbe, C; Mir, O; Pécuchet, N; Tod, M; Viguier, M	1
Bornfeld, N; Freistuehler, M; Hilger, RA; Scheulen, M; Steuhl, KP; Westekemper, H	1
Axelrod, M; Capaldo, BJ; Gioeli, D; Jensen, K; Mackey, A; Roller, DG; Weber, MJ	1
Aparicio, AM; Bhatia, S; Lao, CD; Margolin, KA; Moon, J; Othus, M; Ribas, A; Sondak, VK; Weber, JS	1
Atkins, MB; Flaherty, KT; Flaherty, L; Kefford, R; Kirkwood, JM; Lee, SJ; Leming, P; Schuchter, LM; Zhao, F	1
Chiloeches, A; Friedlos, F; Hayward, R; Hedley, D; Karasarides, M; Marais, R; Marshall, CJ; Martin, J; Niculescu-Duvaz, D; Ogilvie, L; Scanlon, I; Springer, CJ	1
Robertson, GP; Sharma, A; Smith, CD; Trivedi, NR; Tuveson, DA; Zimmerman, MA	1
Atkins, MB; Mier, JW; Panka, DJ; Wang, W	1
Rini, BI	1
Ahmad, T; Eisen, T; Flaherty, KT; Gibbens, I; Gore, M; Hackett, S; James, M; Kaye, S; Marais, R; Nathanson, KL; O'Dwyer, PJ; Poulin-Costello, M; Ratain, MJ; Schuchter, LM; Schwartz, B; Simantov, R; Xia, C	1
Carter, C; Gollob, JA; Kelley, SL; Wilhelm, S	1
Carter, C; Feldman, MD; Lassoued, W; Lee, WM; Makonnen, S; Murphy, DA	1
Angevin, E; Armand, JP; Brendel, E; Chami, L; Escudier, B; Lamuraglia, M; Landreau, V; Lassau, N; Robert, C; Schwartz, B; Soria, JC; Zafarana, E	1
Hauschild, A	1
Busch, S; Garbe, C; Herlyn, M; Kulms, D; Lasithiotakis, K; Maczey, E; Meier, F; Schittek, B	1
Acs, G; Brafford, P; Chen, L; Edwards, R; Herlyn, M; Kazianis, S; Kumar, SM; Xu, X; Yu, H	1
Flaherty, KT	1
Blansfield, JA; Kachala, S; Libutti, SK; Lorang, D; Mangiameli, DP; Muller, GW; Schafer, PH; Stirling, DI	1
Atkins, MB; Cho, DC; Mier, JW; Panka, DJ	1
Flaherty, KT; Garbe, C; Kulms, D; Lasithiotakis, KG; Maczey, E; Meier, FE; Schittek, B; Sinnberg, TW	1
Hersey, P; Hong, A; Moncrieff, M; Shannon, K; Thompson, J	1
Agarwala, S; Beeram, M; Cranmer, L; Frenette, G; Gonzalez, R; Hersh, E; Hodi, FS; Jakub, JW; Kirkwood, J; Lewis, K; Linette, GP; McDermott, DF; Patel, K; Puzanov, I; Richards, J; Sosman, JA; Tarantolo, S; White, JM; Xia, C	1

Reviews

14 review(s) available for sorafenib and Melanoma

Article	Year
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. European journal of cancer (Oxford, England : 1990), 2019, Volume: 123 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib	2019
New insights on the role of autophagy in the pathogenesis and treatment of melanoma. Molecular biology reports, 2020, Volume: 47, Issue:11 Topics: Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Carcinogenesis; Gene Expression; Humans; Melanoma; Skin Neoplasms; Sorafenib	2020
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer, 2017, 06-01, Volume: 123, Issue:S11 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CTLA-4 Antigen; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunotherapy; Indoles; Ipilimumab; MAP Kinase Kinase 1; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib	2017
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. British journal of cancer, 2014, Aug-12, Volume: 111, Issue:4 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Enzyme Activation; Humans; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Multimerization; Protein Processing, Post-Translational; raf Kinases; Sorafenib; Sulfonamides; Vemurafenib	2014
[New molecular target therapy for thyroid neoplasms and malignant melanomas]. Nihon Jibiinkoka Gakkai kaiho, 2015, Volume: 118, Issue:11 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Quinolines; Skin Neoplasms; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib	2015
Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. Onkologie, 2008, Volume: 31, Issue:7 Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Science; Skin Neoplasms; Sorafenib; Treatment Outcome	2008
BRAF signaling and targeted therapies in melanoma. Hematology/oncology clinics of North America, 2009, Volume: 23, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Drug Delivery Systems; Drugs, Investigational; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Humans; Melanoma; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays	2009
BRAF as therapeutic target in melanoma. Biochemical pharmacology, 2010, Sep-01, Volume: 80, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib	2010
Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? Dermatology (Basel, Switzerland), 2010, Volume: 221, Issue:3 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Female; Humans; Male; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib	2010
Sorafenib in melanoma. Expert opinion on investigational drugs, 2012, Volume: 21, Issue:4 Topics: Animals; Benzenesulfonates; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib	2012
Sorafenib. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:4 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays	2006
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Seminars in oncology, 2006, Volume: 33, Issue:4 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Extracellular Signal-Regulated MAP Kinases; Melanoma; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Isoforms; Protein Kinase Inhibitors; Pyridines; raf Kinases; Signal Transduction; Sorafenib	2006
[Clinical studies with sorafenib (Nexavar) in metastatic melanoma]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2007, Volume: 5, Issue:4 Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib; Treatment Outcome	2007
Sorafenib: delivering a targeted drug to the right targets. Expert review of anticancer therapy, 2007, Volume: 7, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib	2007

Trials

23 trial(s) available for sorafenib and Melanoma

Article	Year
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial). Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2013, Volume: 11, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Causality; Comorbidity; Drug Eruptions; Female; Germany; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Prevalence; Recombinant Proteins; Risk Factors; Skin Neoplasms; Sorafenib; Treatment Outcome	2013
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering. Cancer research, 2014, Jan-01, Volume: 74, Issue:1 Topics: Adult; Aged; CD4 Antigens; Cell Growth Processes; Female; Humans; Interleukin-15; Interleukin-15 Receptor alpha Subunit; Male; Melanoma; Middle Aged; Niacinamide; NK Cell Lectin-Like Receptor Subfamily K; Phenylurea Compounds; Sorafenib; Th1 Cells; Young Adult	2014
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma. Journal of immunotherapy (Hagerstown, Md. : 1997), 2014, Volume: 37, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Interleukin-2; Kidney Neoplasms; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; STAT5 Transcription Factor; T-Lymphocytes, Regulatory	2014
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jun-15, Volume: 20, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Double-Blind Method; Female; Follow-Up Studies; Genotype; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Survival Rate	2014
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Disease Progression; Drug Monitoring; Early Termination of Clinical Trials; Feasibility Studies; Female; Hand-Foot Syndrome; Humans; Hypertension; Kinetics; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Sorafenib; Vascular Endothelial Growth Factors	2014
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. The oncologist, 2015, Volume: 20, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib	2015
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Jan-15, Volume: 22, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; DNA Copy Number Variations; DNA Mutational Analysis; Double-Blind Method; Genes, ras; Humans; Melanoma; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Sorafenib; Treatment Outcome	2016
Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study. British journal of cancer, 2016, Jun-28, Volume: 115, Issue:1 Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Male; Melanoma; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Uveal Neoplasms	2016
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-01, Volume: 15, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Cell Line, Tumor; Disease-Free Survival; Drug Delivery Systems; Humans; Melanoma; Mitogen-Activated Protein Kinase 3; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib; Treatment Outcome	2009
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jul-15, Volume: 16, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzoquinones; Clinical Trials, Phase II as Topic; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lactams, Macrocyclic; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis	2010
A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PloS one, 2010, Dec-29, Volume: 5, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Cyclin D1; DNA Mutational Analysis; Female; Humans; Ki-67 Antigen; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sequence Analysis, DNA; Signal Transduction; Sorafenib	2010
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Benzenesulfonates; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Prospective Studies; Pyridines; Recombinant Proteins; Sorafenib; Survival Rate; Treatment Outcome; Young Adult	2011
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:5 Topics: Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Isoenzymes; Melanoma; Midazolam; Niacinamide; Omeprazole; Phenylurea Compounds; Pyridines; Sorafenib	2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. British journal of cancer, 2011, Jul-26, Volume: 105, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib	2011
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Feb-15, Volume: 18, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult	2012
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Feb-15, Volume: 18, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome	2012
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. Annals of surgical oncology, 2012, Volume: 19, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Extremities; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Melphalan; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Array Analysis; Skin Neoplasms; Sorafenib; Tissue Distribution	2012
Sorafenib in advanced melanoma: a critical role for pharmacokinetics? British journal of cancer, 2012, Jul-24, Volume: 107, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib	2012
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PloS one, 2012, Volume: 7, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Eye Neoplasms; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib; Treatment Outcome; Uvea; Uveal Neoplasms	2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-20, Volume: 31, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib	2013
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. British journal of cancer, 2006, Sep-04, Volume: 95, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; DNA Primers; Female; Genes, ras; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Proto-Oncogene Proteins B-raf; Pyridines; Safety; Sorafenib	2006
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Mar-15, Volume: 13, Issue:6 Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Immune System; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Treatment Outcome	2007
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-01, Volume: 26, Issue:13 Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome; United States	2008

Other Studies

86 other study(ies) available for sorafenib and Melanoma

Article	Year
Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. Bioorganic & medicinal chemistry letters, 2007, Aug-01, Volume: 17, Issue:15 Topics: Cell Line, Tumor; Cell Proliferation; Humans; Melanoma; Thiazolidines	2007
Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma. Bioorganic & medicinal chemistry letters, 2008, Jun-01, Volume: 18, Issue:11 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Imidazolines; Melanoma; Structure-Activity Relationship; Thiazolidines	2008
Aminoquinoline derivatives with antiproliferative activity against melanoma cell line. Bioorganic & medicinal chemistry letters, 2009, Jul-01, Volume: 19, Issue:13 Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Melanoma	2009
Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. Journal of medicinal chemistry, 2009, Jul-09, Volume: 52, Issue:13 Topics: Allosteric Site; Antineoplastic Agents; Inhibitory Concentration 50; Melanoma; Mutation, Missense; Phenols; Proto-Oncogene Proteins B-raf; Pyridines; Structure-Activity Relationship	2009
Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line. Bioorganic & medicinal chemistry letters, 2009, Dec-01, Volume: 19, Issue:23 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Melanoma; Molecular Structure; Pyrimidines; Pyrroles; Stereoisomerism; Structure-Activity Relationship	2009
Synthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma. Bioorganic & medicinal chemistry letters, 2010, Jan-01, Volume: 20, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Structure-Activity Relationship	2010
Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines. Bioorganic & medicinal chemistry letters, 2010, Mar-01, Volume: 20, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Drug Discovery; Humans; Imidazoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-raf; Pyridines; Pyrimidines; Sorafenib; Structure-Activity Relationship	2010
1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors. Bioorganic & medicinal chemistry letters, 2010, Jun-15, Volume: 20, Issue:12 Topics: Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Inhibitory Concentration 50; Melanoma; Protein Kinase Inhibitors; raf Kinases; Structure-Activity Relationship	2010
Synthesis of aminoquinazoline derivatives and their antiproliferative activities against melanoma cell line. Bioorganic & medicinal chemistry letters, 2010, Oct-01, Volume: 20, Issue:19 Topics: Antineoplastic Agents; Cell Line, Tumor; Chromones; Humans; Melanoma; Quinazolines; Structure-Activity Relationship	2010
Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells. Bioorganic & medicinal chemistry, 2011, Mar-15, Volume: 19, Issue:6 Topics: Amides; Antineoplastic Agents; Benzenesulfonates; Binding Sites; Cell Line, Tumor; Computer Simulation; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyridines; raf Kinases; Sorafenib; Structure-Activity Relationship	2011
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. European journal of medicinal chemistry, 2011, Volume: 46, Issue:8 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Melanoma; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Skin Neoplasms; Sorafenib; Structure-Activity Relationship	2011
New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies. European journal of medicinal chemistry, 2011, Volume: 46, Issue:12 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; MAP Kinase Signaling System; Melanoma; Models, Molecular; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazoles; Structure-Activity Relationship	2011
Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells. Bioorganic & medicinal chemistry, 2011, Nov-15, Volume: 19, Issue:22 Topics: Amides; Azepines; Cell Growth Processes; Cell Line, Tumor; Humans; Melanoma; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Pyrazoles; Structure-Activity Relationship; U937 Cells	2011
New imidazo[2,1-b]thiazole derivatives: synthesis, in vitro anticancer evaluation, and in silico studies. European journal of medicinal chemistry, 2011, Volume: 46, Issue:12 Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Structure-Activity Relationship; Thiazoles	2011
Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors. European journal of medicinal chemistry, 2012, Volume: 50 Topics: Cell Line, Tumor; Cell Proliferation; Chalcone; Chalcones; Drug Design; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Melanoma; Molecular Structure; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Structure-Activity Relationship; Sulfones	2012
New diarylureas and diarylamides possessing acet(benz)amidophenyl scaffold: design, synthesis, and antiproliferative activity against melanoma cell line. Bioorganic & medicinal chemistry letters, 2012, May-01, Volume: 22, Issue:9 Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Melanoma; Urea	2012
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Part 2. Bioorganic & medicinal chemistry letters, 2012, Jul-01, Volume: 22, Issue:13 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Humans; Melanoma; Pyridines; Pyrroles; Structure-Activity Relationship	2012
Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents. Bioorganic & medicinal chemistry letters, 2012, Nov-01, Volume: 22, Issue:21 Topics: Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50; Melanoma; Phosphorylation; Protein Binding; Proto-Oncogene Proteins B-raf; Pyrazoles; Quantitative Structure-Activity Relationship; Salicylamides	2012
New diarylamides and diarylureas possessing 8-amino(acetamido)quinoline scaffold: synthesis, antiproliferative activities against melanoma cell lines, kinase inhibition, and in silico studies. European journal of medicinal chemistry, 2013, Volume: 70 Topics: Acetamides; Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship; Urea	2013
Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents. European journal of medicinal chemistry, 2013, Volume: 70 Topics: Antineoplastic Agents; Benzazepines; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; HCT116 Cells; Hep G2 Cells; Humans; Indoles; K562 Cells; Melanoma; Molecular Structure; Niacinamide; Phenylurea Compounds; Quinolones; Sorafenib; Structure-Activity Relationship; Sulfonamides; Vemurafenib	2013
Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance. European journal of medicinal chemistry, 2017, Apr-21, Volume: 130 Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Humans; Melanoma; Protein Kinase Inhibitors; Pyrimidines; raf Kinases; Rats	2017
Arginase 2 negatively regulates sorafenib-induced cell death by mediating ferroptosis in melanoma. Acta biochimica et biophysica Sinica, 2022, Nov-25, Volume: 54, Issue:11 Topics: Arginase; Cell Death; Ferroptosis; Humans; Melanoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sorafenib	2022
Effective Synergy of Sorafenib and Nutrient Shortage in Inducing Melanoma Cell Death through Energy Stress. Cells, 2020, 03-06, Volume: 9, Issue:3 Topics: Antineoplastic Agents; Autophagy; Cell Death; Humans; Melanoma; Nutrients; Sorafenib; Tumor Microenvironment	2020
Sorafenib induces pigmentation via the regulation of β-catenin signalling pathway in melanoma cells. Experimental dermatology, 2022, Volume: 31, Issue:1 Topics: Antineoplastic Agents; beta Catenin; Cell Line, Tumor; Humans; Melanoma; Pigmentation; Signal Transduction; Skin Neoplasms; Sorafenib	2022
Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies. Journal of enzyme inhibition and medicinal chemistry, 2020, Volume: 35, Issue:1 Topics: Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Molecular Dynamics Simulation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quantitative Structure-Activity Relationship; Sorafenib; Sulfonamides; Thiazoles; Vemurafenib	2020
Assessment of sorafenib induced changes in tumor perfusion of uveal melanoma metastases with dynamic contrast-enhanced ultrasound (DCE-US). Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:4 Topics: Contrast Media; Humans; Melanoma; Perfusion; Prospective Studies; Sorafenib; Ultrasonography; Uveal Neoplasms	2022
Sorafenib induces synergistic effect on inhibition of vemurafenib resistant melanoma growth. Frontiers in bioscience (Scholar edition), 2019, 03-01, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Inhibitory Concentration 50; Melanoma; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib	2019
Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BMJ case reports, 2019, Jun-20, Volume: 12, Issue:6 Topics: BRCA2 Protein; Carcinoma, Renal Cell; Chemoradiotherapy, Adjuvant; Female; Germ-Line Mutation; Humans; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Multiple Primary; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome	2019
Innovations in the treatment of melanoma. Journal of the National Comprehensive Cancer Network : JNCCN, 2004, Volume: 2 Suppl 3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cancer Vaccines; DNA, Antisense; Genetic Therapy; Humans; Immunologic Factors; Melanoma; Niacinamide; Phenylurea Compounds; Proteasome Inhibitors; Sorafenib	2004
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-01, Volume: 31, Issue:19 Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Indoles; Leucine; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Niacinamide; Oximes; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib	2013
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment cell & melanoma research, 2013, Volume: 26, Issue:6 Topics: Adolescent; Adult; Child, Preschool; Enzyme Activation; Female; Gene Rearrangement; Humans; Indoles; Male; MAP Kinase Signaling System; Melanocytes; Melanoma; Middle Aged; Molecular Targeted Therapy; Nevus, Epithelioid and Spindle Cell; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib; Young Adult	2013
Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib. Acta ophthalmologica, 2014, Volume: 92, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Uveal Neoplasms	2014
Molecular ultrasound imaging using contrast agents targeting endoglin, vascular endothelial growth factor receptor 2 and integrin. Ultrasound in medicine & biology, 2015, Volume: 41, Issue:1 Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Contrast Media; Endoglin; Female; Integrin alphaV; Intracellular Signaling Peptides and Proteins; Melanoma; Mice; Mice, Nude; Molecular Imaging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2	2015
Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2015, Apr-28, Volume: 112, Issue:17 Topics: Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Collagenases; Humans; Hydrogels; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Tissue Scaffolds; Vemurafenib	2015
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts. Journal of translational medicine, 2015, Jun-13, Volume: 13 Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays	2015
Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Oncotarget, 2015, Sep-29, Volume: 6, Issue:29 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Flavonoids; Flavonols; Humans; Immunohistochemistry; Melanoma; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays	2015
Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma. Oncotarget, 2016, Jan-12, Volume: 7, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cadherins; Cell Line, Tumor; Cell Movement; Cells, Cultured; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Flavonoids; Flavonols; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Melanoma; Mice, Nude; Mutation; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays	2016
A case series of anal melanoma including the results of treatment with imatinib in selected patients. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2016, Volume: 18, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Agents; Anus Neoplasms; Dacarbazine; Digestive System Surgical Procedures; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Retrospective Studies; Sorafenib; Survival Rate	2016
B-Raf Inhibition in the Clinic: Present and Future. Annual review of medicine, 2016, Volume: 67 Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Oximes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib	2016
Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin. PloS one, 2016, Volume: 11, Issue:5 Topics: Cell Line, Tumor; Cell Proliferation; Genes, ras; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Receptors, Retinoic Acid; Sorafenib; Xanthones	2016
Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jun-01, Volume: 14, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Ceramides; Drug Synergism; Humans; Liposomes; Melanoma; Mitogen-Activated Protein Kinases; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib	2008
Effectively targeting BRAF in melanoma: a formidable challenge. Pigment cell & melanoma research, 2008, Volume: 21, Issue:4 Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides; Treatment Outcome	2008
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-20, Volume: 26, Issue:24 Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polycythemia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib	2008
Searching for the Achilles' heel of melanoma cells: new treatment modalities. Pigment cell & melanoma research, 2008, Volume: 21, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Clinical Trials as Topic; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Melanoma; Niacinamide; Organoselenium Compounds; Phenylurea Compounds; Pyridines; Pyrimethamine; Skin Neoplasms; Sorafenib; Treatment Outcome; Urea; Vascular Endothelial Growth Factor Receptor-2	2008
Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect. Journal of the European Academy of Dermatology and Venereology : JEADV, 2009, Volume: 23, Issue:8 Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Humans; Hyperplasia; Lung Neoplasms; Male; Melanoma; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Pyridines; Skin; Skin Diseases; Skin Neoplasms; Sorafenib	2009
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene, 2009, Jan-08, Volume: 28, Issue:1 Topics: Apoptosis; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glutamic Acid; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Valine	2009
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. Journal of translational medicine, 2008, Sep-29, Volume: 6 Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Melanoma; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyridines; Pyrimidines; Receptor, EphA2; Sorafenib; Temozolomide; Thiazoles	2008
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nature clinical practice. Oncology, 2008, Volume: 5, Issue:12 Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzenesulfonates; Dacarbazine; Humans; Male; Melanoma; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Temozolomide; Treatment Outcome	2008
Targeting metastatic melanoma. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Dec-15, Volume: 65, Issue:24 Suppl 9 Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Agents; Benzenesulfonates; Cancer Vaccines; Clinical Trials as Topic; CTLA-4 Antigen; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Skin Neoplasms; Sorafenib; Thionucleotides	2008
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. Molecular cancer therapeutics, 2009, Volume: 8, Issue:3 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Quinoxalines; Skin Neoplasms; Sorafenib; Substrate Specificity; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2009
Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:28-29 Topics: Abdomen, Acute; Aged; Antineoplastic Agents; Benzenesulfonates; Colectomy; Colonic Diseases; Diarrhea; Fatal Outcome; Humans; Ileostomy; Intestinal Perforation; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib; Ulcer	2009
Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future oncology (London, England), 2009, Volume: 5, Issue:6 Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Humans; Imatinib Mesylate; Imidazoles; Inhibitory Concentration 50; Melanoma; Mice; Microsomes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Sorafenib	2009
Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma. Pediatric blood & cancer, 2010, Volume: 54, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Child, Preschool; Cyclophosphamide; Dacarbazine; Female; Humans; Melanoma; Melanosis; Meningeal Neoplasms; Neurocutaneous Syndromes; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide; Treatment Outcome	2010
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Sep-15, Volume: 15, Issue:18 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cohort Studies; Disease Progression; Female; Gene Silencing; Humans; Indoles; Male; Melanoma; Middle Aged; Nevus; Niacinamide; Phenols; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Sensitivity and Specificity; Skin Neoplasms; Sorafenib; Young Adult	2009
The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. International journal of cancer, 2010, Apr-01, Volume: 126, Issue:7 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Colony-Forming Units Assay; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique; Furans; Humans; Immunoenzyme Techniques; Immunosuppression Therapy; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrimidines; ras Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Tumor Cells, Cultured	2010
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Molecular cell, 2009, Nov-13, Volume: 36, Issue:3 Topics: Animals; Benzenesulfonates; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Enzyme Activation; Humans; Immunoprecipitation; MAP Kinase Signaling System; Melanoma; Mice; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; ras Proteins; Sorafenib; Transfection	2009
Optimal de novo design of MRM experiments for rapid assay development in targeted proteomics. Journal of proteome research, 2010, May-07, Volume: 9, Issue:5 Topics: Algorithms; Animals; Artificial Intelligence; Benzenesulfonates; Cell Line, Tumor; Chromatography, High Pressure Liquid; Female; Humans; Linear Models; Markov Chains; Mass Spectrometry; Melanoma; Mice; Niacinamide; Peptide Fragments; Phenylurea Compounds; Proteome; Proteomics; Pyridines; Reproducibility of Results; Sorafenib	2010
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. British journal of cancer, 2010, Apr-13, Volume: 102, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Skin Neoplasms; Sorafenib	2010
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Molecular cancer therapeutics, 2010, Volume: 9, Issue:7 Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Butadienes; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Melanoma; Melphalan; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Nude; Sorafenib; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays	2010
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. The Journal of investigative dermatology, 2011, Volume: 131, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Benzenesulfonates; Cell Line, Tumor; Endoplasmic Reticulum; Farnesyltranstransferase; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factor CHOP	2011
Oncogenic RAF: a brief history of time. Pigment cell & melanoma research, 2010, Volume: 23, Issue:6 Topics: Benzenesulfonates; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides; Time Factors; Vemurafenib	2010
Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. Archives of dermatology, 2010, Volume: 146, Issue:12 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Drug Administration Routes; Follow-Up Studies; Humans; Leg; Male; Melanoma; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib	2010
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-15, Volume: 17, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; Clinical Trials, Phase II as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Survival Analysis; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2011
B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger. The Journal of biological chemistry, 2011, Apr-15, Volume: 286, Issue:15 Topics: Amino Acid Substitution; Animals; Benzenesulfonates; Cation Transport Proteins; Cell Movement; Cell Size; Extracellular Signal-Regulated MAP Kinases; HEK293 Cells; HeLa Cells; Humans; Hydrogen-Ion Concentration; Indoles; Melanoma; Mutation, Missense; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Isoforms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins B-raf; Pyridines; Rabbits; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfonamides	2011
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Molecular therapy : the journal of the American Society of Gene Therapy, 2011, Volume: 19, Issue:6 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Hep G2 Cells; Humans; Liver Neoplasms; Melanoma; Mice; Mice, SCID; Niacinamide; Oncolytic Virotherapy; Phenylurea Compounds; Pyridines; Sorafenib; Vaccinia virus; Xenograft Model Antitumor Assays	2011
Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells. American journal of physiology. Cell physiology, 2011, Volume: 301, Issue:3 Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL1; Chemokine CXCL5; Dichlororibofuranosylbenzimidazole; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Genes, Reporter; Half-Life; Humans; Immunotherapy, Active; Interleukin-8; Leupeptins; MAP Kinase Kinase Kinases; Melanoma; Membrane Proteins; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyridines; Receptors, Interleukin-8B; RNA Stability; RNA, Messenger; RNA, Small Interfering; Sorafenib; Transfection; Tristetraprolin; Tumor Cells, Cultured; Vaccination	2011
[News on melanoma from the 2010 Dermatology Days in Paris]. Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:5 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Dermatology; Evidence-Based Medicine; Humans; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Radiotherapy, Adjuvant; Skin Neoplasms; Sorafenib; Temozolomide; Treatment Outcome	2011
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. The Journal of investigative dermatology, 2011, Volume: 131, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Genes, Dominant; Humans; Indoles; Melanocytes; Melanoma; Niacinamide; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Fibroblast Growth Factor; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib	2011
Setting up a kinase discovery and development project. Current topics in microbiology and immunology, 2012, Volume: 355 Topics: Adenosine Triphosphate; Animals; Crystallography, X-Ray; Drug Discovery; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Enzyme Activation; Enzyme Assays; Humans; Indoles; Melanoma; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Solubility; Sorafenib; Structure-Activity Relationship; Sulfonamides	2012
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Nov-15, Volume: 17, Issue:22 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glutamic Acid; Indoles; Melanoma; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays	2011
Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. Molecular cancer, 2011, Sep-19, Volume: 10 Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Gene Expression; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Melanoma; Mice; Mice, Nude; Mitochondria; Necrosis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Transport; Proto-Oncogene Proteins c-mdm2; Pyridines; RNA Interference; Sorafenib; Spiro Compounds; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2011
Design, synthesis, and antiproliferative activity of 3,4-diarylpyrazole-1-carboxamide derivatives against melanoma cell line. Archiv der Pharmazie, 2011, Volume: 344, Issue:11 Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyridines; Sorafenib; Structure-Activity Relationship	2011
Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways. Anticancer research, 2011, Volume: 31, Issue:10 Topics: Anthracenes; Benzenesulfonates; Cell Death; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; Melanoma; Morpholines; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib	2011
Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy? Experimental dermatology, 2011, Volume: 20, Issue:12 Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Butadienes; Cell Survival; Dacarbazine; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fatal Outcome; Female; Genes, ras; Humans; Melanoma; Molecular Targeted Therapy; Mutation; Niacinamide; Nitriles; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Phosphorylation; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyridines; Signal Transduction; Sorafenib; Treatment Outcome	2011
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2013, Volume: 251, Issue:1 Topics: Antineoplastic Agents; Benzophenones; Boronic Acids; Bortezomib; Cell Proliferation; Conjunctival Neoplasms; Drug Screening Assays, Antitumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyrazines; Ribonucleases; Sorafenib; Tumor Cells, Cultured	2013
Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Molecular cancer therapeutics, 2012, Volume: 11, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Diclofenac; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Phospholipases A2, Cytosolic; Signal Transduction; Skin Neoplasms; Small Molecule Libraries; Sorafenib	2012
B-RAF is a therapeutic target in melanoma. Oncogene, 2004, Aug-19, Volume: 23, Issue:37 Topics: Benzenesulfonates; Cell Line, Tumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib	2004
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer research, 2005, Mar-15, Volume: 65, Issue:6 Topics: Animals; Apoptosis; Benzenesulfonates; Cell Growth Processes; Cell Line, Tumor; Humans; MAP Kinase Signaling System; Melanoma; Mice; Mutation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; RNA, Small Interfering; Sorafenib; Vascular Endothelial Growth Factor A	2005
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer research, 2006, Feb-01, Volume: 66, Issue:3 Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; Benzenesulfonates; Caspases; Cell Line, Tumor; Cell Nucleus; Cytochromes c; Humans; Intracellular Signaling Peptides and Proteins; Melanoma; Mitochondria; Mitochondrial Proteins; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Sorafenib	2006
Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). The American journal of pathology, 2006, Volume: 169, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Collagen; Drug Combinations; Endothelial Cells; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Humans; Kidney Neoplasms; Laminin; Melanoma; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteoglycans; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib	2006
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. The British journal of dermatology, 2007, Volume: 156, Issue:6 Topics: Androstadienes; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dimethyl Sulfoxide; Humans; MAP Kinase Signaling System; Melanoma; Neoplasm Invasiveness; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib; Wortmannin	2007
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer research, 2007, Apr-01, Volume: 67, Issue:7 Topics: Benzenesulfonates; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; RNA Interference; RNA, Small Interfering; Sorafenib; Transfection; Up-Regulation	2007
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. Journal of translational medicine, 2007, Jul-18, Volume: 5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Movement; Cell Proliferation; Disease Models, Animal; Endothelial Cells; Eye Neoplasms; Humans; In Vitro Techniques; Lenalidomide; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Thalidomide; Xenograft Model Antitumor Assays	2007
GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. The Journal of biological chemistry, 2008, Jan-11, Volume: 283, Issue:2 Topics: Apoptosis; Benzenesulfonates; Cell Adhesion; Cell Death; Cell Line, Tumor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Melanoma; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib	2008
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. The Journal of investigative dermatology, 2008, Volume: 128, Issue:8 Topics: Androstadienes; Apoptosis; Benzenesulfonates; Butadienes; Cell Line, Tumor; Cell Proliferation; Chromones; Down-Regulation; Flavonoids; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mitogen-Activated Protein Kinase Kinases; Morpholines; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sirolimus; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Wortmannin	2008
Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy. Melanoma research, 2008, Volume: 18, Issue:2 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Lower Extremity; Lymphatic Metastasis; Lymphedema; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib	2008